Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes, mu, delta and kappa, whose genes have been cloned. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, in animal models, dopamine D1 receptor knockout rats will not self-administer cocaine37 and μ opioid receptor knockout mice will not show the rewarding effects of opioids.153”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [153]
In the citing paper
“Mice that lack the MOR gene do not develop place preferences or withdrawal symptoms in response to morphine (Matthes et al 1996).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Matthes et al 1996
Citations
Cites
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., & Hirth, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12048 · Cited by 1,010
Self-citationNeutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.
Roques, B. P., Noble, F., Daugé, V, Fournié-Zaluski, M. C., & Beaumont, A. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00449-1 · Cited by 756
Self-citationLufkin, T., Dierich, A., LeMeur, M., Mark, M., & Chambon, P. (1991) · Cell · doi:10.1016/0092-8674(91)90034-v · Cited by 697
Self-citationChiara, G. D., & Alan North, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90062-b · Cited by 543
Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., & Nestler, E. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)91111-d · Cited by 535
A brief history of opiates, opioid peptides, and opioid receptors.
Brownstein, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5391 · Cited by 491
Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
Goldstein, A., & Naidu, A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09190-4 · Cited by 445
Kieffer, B. L. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071128 · Cited by 389
Self-citationReduction of Morphine Abstinence in Mice with a Mutation in the Gene Encoding CREB
Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J., & Schütz, G. (1996) · Science · doi:10.1126/science.273.5275.657 · Cited by 292
Self-citationThe mouse Pgk-1 gene promoter contains an upstream activator sequence
McBurney, M. W., Sutherland, L. C., Adra, C. N., Leclair, B., Rudnicki, M. A., & Jardine, K. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5755 · Cited by 193
Research works printed but not linked: 9
- Goldstein, A. & Naidu, A. Mol. Pharmacol. 36, 265–272 (1989).
- Pasternak, G. W. Clin. Pharmacol. 16, 1–18 (1993).
- Cowan, A. in Handbook of Experimental Pharmacology Opioids II (ed. Herz, A.) Vol. 104, 393–414 (Springer, Berlin, 1993).
- Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M.-C. & Beaumont, A. Pharmacol. Rev. 45, 87–146 (1993).
- Baamonde, A., Daugé, V., Gacel, C. & Roques, B. P. J. Pharmacol. Exp. Ther. 257, 767–773 (1991).
- Koob, G. F. Trends Biochem. Sci. 13, 177–184 (1992).
- Wei, E. T. J. Pharmacol. Exp. Ther. 216, 12–18 (1981).
- Cowan, A., Zhu, X. Z., Mosberg, H. I., Omnaas, J. R. & Porreca, F. J. Pharmacol. Exp. Ther. 246, 950–955 (1988).
- Kitchen, I. et al. J. Pharmacol. Exp. Ther. 275, 1595–1607 (1995).
Cited by
Items 201–300 of 1,002
Molecular Biology of Opioid Analgesia
Pasternak, G. W. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2005.01.011 · Cited by 140
Sora, I., Elmer, G., Funada, M., Pieper, J., Li, X. F., Hall, F. S., & Uhl, G. R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00252-9 · Cited by 172
“Homozygous knockout mice display no detectable receptor binding or immunoreactivity, although they contain near-normal complements of and receptors and of the mRNAs encoding these receptors, preproenkephalin, preprodynorphin, and preproopiomelanocortin (Matthes et al. 1996; Sora et al. 1997b).”
BackgroundInfluentialSuspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine
Lydecker, A. G., Sharma, A., McCurdy, C. R., Avery, B. A., Babu, K. M., & Boyer, E. W. (2016) · Journal of Medical Toxicology · doi:10.1007/s13181-016-0588-y · Cited by 142
“Well established is the knowledge that morphine tolerance and physical dependence are secondary to mu-opioid receptor agonism [28, 29].”
BackgroundZADINA, J. E., MARTIN‐SCHILD, S., GERALL, A. A., KASTIN, A. J., HACKLER, L., GE, L., & ZHANG, X. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07885.x · Cited by 136
Phosphorylation of EEA1 by p38 MAP kinase regulates μ opioid receptor endocytosis
Macé‐Aimé, G., Miączyńska, M., Zerial, M., & Nebreda, Á. R. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600799 · Cited by 152
“Studies using opioid receptor knockout mice have demon- strated that MOR mediates all morphine biological effects, both beneficial and adverse (Matthes et al, 1996; Kieffer, 1999).”
BackgroundDoll, C., Konietzko, J., Pöll, F., Koch, T., Höllt, V., & Schulz, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01382.x · Cited by 133
“Morphine exerts all of its biological effects by interacting with the m-opioid receptor (Matthes et al., 1996).”
BackgroundA genetic association study of the mu opioid receptor and severe opioid dependence
Crowley, J. J., Oslin, D. W., Patkar, A. A., Gottheil, E., DeMaria, P. A., O??Brien, C. P., Berrettini, W. H., & Grice, D. E. (2003) · Psychiatric Genetics · doi:10.1097/00041444-200309000-00006 · Cited by 135
“The mu opioid receptor mediates several properties of morphine, including the rewarding effects and the development of tolerance and dependence (Matthes et al., 1996).”
BackgroundWeibel, R., Reiss, D. J., Karchewski, L. A., Gardon, O., Matifas, A., Filliol, D., Becker, J. A. J., Wood, J. N., Kieffer, B. L., & Gavériaux‐Ruff, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074706 · Cited by 147
“Conventional Oprm1 knockout animals [17] were also used in the tail immersion, hot plate, and capsaicin assays to verify the selectivity of morphine for the mu receptor in these tests.”
MethodSelf-citationAllostery at opioid receptors: modulation with small molecule ligands
Livingston, K. E., & Traynor, J. R. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13823 · Cited by 134
“However, while activation of μ-receptors provides pain relief, it also results in a wide range of unwanted effects including constipation and life-threatening respiratory depression, as well as rewarding effects that lead to addiction liability (Matthes et al., 1996).”
BackgroundHale, M. E., Upmalis, D. H., Okamoto, A., Lange, C., & Rauschkolb, C. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902816970 · Cited by 137
Proteasome Involvement in Agonist-induced Down-regulation of μ and δ Opioid Receptors
Chaturvedi, K., Bandari, P., Chinen, N., & Howells, R. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008054200 · Cited by 133
Daniels, S., Casson, E., Stegmann, J., Oh, C., Okamoto, A., Rauschkolb, C., & Upmalis, D. H. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902952825 · Cited by 136
“Black* 12 (17) 67 (24) 54 (19) 67 (24) 200 (22) Hispanicy 26 (38) 68 (25) 83 (30) 64 (23) 241 (27) Otherz 4 (6) 11 (4) 15 (5) 16 (6) 46 (5) BMI, kg/m(2)”
Okude, J., Ueda, T., Kofuku, Y., Sato, M., Nobuyama, N., Kondo, K., Shiraishi, Y., Mizumura, T., Onishi, K., Natsume, M., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508794 · Cited by 137
Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies
Katia, B. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00006 · Cited by 130
Self-citationBiased mu-opioid receptor ligands: a promising new generation of pain therapeutics
Siuda, E. R., Carr, R., Rominger, D. H., & Violin, J. D. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.11.007 · Cited by 147
“Opioids like morphine were inferred to rely on an opioid-specific receptor, but it was not until the specific binding [4] and subsequent genetic deletion of the mu opioid receptor (MOR) in mice [5,6] that the mechanism of action was verified to require a membrane-bound protein responsible for both opioid as well as en…”
BackgroundFormisano, L., Noh, K.-M., Miyawaki, T., Mashiko, T., Bennett, M. V. L., & Zukin, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611704104 · Cited by 145
Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?
Zaki, P. A., Keith, D. E., Brine, G. A., Carroll, F. I., & Evans, C. J. (2000) · PubMed · Cited by 129
The μ-opioid receptor is necessary for [d-Pen2,d-Pen5]enkephalin-induced analgesia
Sora, I., Funada, M., & Uhl, G. R. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)10016-4 · Cited by 129
Chartoff, E. H., & Connery, H. S. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00116 · Cited by 154
“The physiological effects of morphine are absent in mice lacking MORs (Matthes et al., 1996; Le Merrer et al., 2009), providing strong support for the idea that MORs are necessary for the clinically relevant effects of opiates.”
BackgroundWertheim, H. F. L., Vos, M. D., Ott, A., Voß, A., Kluytmans, J. A. J. W., Vandenbroucke‐Grauls, C. M. J. E., Meester, M. H. M., van Keulen, P. H. J., & Verbrugh, H. A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-6-200403160-00007 · Cited by 146
Ma, W., & Quirion, R. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.307 · Cited by 136
“4 Opioids and TRPV1 The μ-opioid receptor (MOR) is the subtype mostly responsible for morphine-induced antinociceptive effects [71].”
BackgroundDifferentiation of Opioid Drug Effects by Hierarchical Multi-Site Phosphorylation
Just, S., Illing, S., Trester-Zedlitz, M., Lau, E. K., Kotowski, S. J., Miess, E., Mann, A., Doll, C., Trinidad, J. C., Burlingame, A. L., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.082875 · Cited by 127
“The primary mechanism by which most of these drugs work is by binding to the μ-type opioid neuropeptide receptor (MOR), and this receptor mediates essentially all of the acute pharmacological actions of morphine (Handa et al., 1981; Matthes et al., 1996).”
BackgroundMorinville, A., Cahill, C. M., Esdaile, M. J., Aibak, H., Collier, B., Kieffer, B. L., & Beaudet, A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04888.2003 · Cited by 146
“…binding studies with DPDPE and deltorphin-I, which also detected no major compensatory changes in total OR expression in the brain of OR KO mice (Matthes et al., 1996; Kitchen et al., 1997; Sora et al., 1997; Loh et al., 1998; Chen et al., 2000) (for review, see Kieffer and Gavériaux-Ruff,…”
BackgroundMethodSelf-citationAutistic-Like Syndrome in Mu Opioid Receptor Null Mice is Relieved by Facilitated mGluR4 Activity
Becker, J. A. J., Clesse, D., Spiegelhalter, C., Schwab, Y., Merrer, J. L., & Kieffer, B. L. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.59 · Cited by 137
“Male and female Oprm1þ /þ and Oprm1 / mice (Matthes et al, 1996) aged 6–8 weeks were bred in-house on an identical hybrid background: 50% 129SVPas–50% C57BL/ 6J.”
MethodSelf-citationElucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists
Claff, T., Yu, J., Blais, V., Patel, N., Martin, C., Wu, L., Han, G. W., Holleran, B. J., der Poorten, O. V., White, K. L., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax9115 · Cited by 137
“We performed molecular docking of several small-molecule analogs of DPI-287 at the DOP, MOP, and KOP (table S3).”
InfluentialThe Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
Dalefield, M. L., Scouller, B., Bibi, R., & Kivell, B. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837671 · Cited by 145
“Although MOR agonists are effective at treating acute pain, they are largely ineffective when used long-term because they induce hyperalgesia and tolerance (Matthes et al., 1996; Chu et al., 2006; Rowbotham and Wallace, 2020), and, with the exception of treating cancer pain, they are not intended as first-line chronic…”
BackgroundWang, D., Raehal, K. M., Bilsky, E. J., & Sadée, W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00362.x · Cited by 126
“The m opioid receptor (MOR), considered the main mediator of narcotic analgesia and addiction (Matthes et al. 1996), exhibits basal signaling activity in SH-SY5Y cells and transfected HEK293 cells via Gai/Gao proteins (Wang et al. 1994; Burford et al. 2000).”
BackgroundSelley, D. E., Cao, C., Sexton, T., Schwegel, J. A., Martin, T. J., & Childers, S. R. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00689-x · Cited by 126
Biased ligands at opioid receptors: Current status and future directions
Che, T., Dwivedi‐Agnihotri, H., Shukla, A. K., & Roth, B. L. (2021) · Science Signaling · doi:10.1126/scisignal.aav0320 · Cited by 136
“Note also that almost all of the currently marketed opioid drugs exert their analgesic effects through the -OR (79).”
BackgroundMu opioid receptor-dependent and independent components in effects of tramadol
Ide, S., Minami, M., Ishihara, K., Uhl, G. R., Sora, I., & Ikeda, K. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.05.008 · Cited by 124
Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action
Kim, K.-S., Lee, K.-W., Lee, K.-W., Im, J.-Y., Yoo, J. Y., Kim, S.-W., Lee, J.-K., Nestler, E. J., & Han, P.-L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508812103 · Cited by 123
GENETIC MODELS OF OBESITY AND ENERGY BALANCE IN THE MOUSE
Robinson, S. W., Dinulescu, D. M., & Cone, R. D. (2000) · Annual Review of Genetics · doi:10.1146/annurev.genet.34.1.687 · Cited by 131
Stefano, G. B., Goumon, Y., Casares, F., Cadet, P., Fricchione, G. L., Rialas, C., Peter, D., Sonetti, D., Guarna, M., Welters, I. D., et al. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01611-8 · Cited by 117
Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation
Cahill, C. M., Walwyn, W., Taylor, A. M. W., Pradhan, A. A. A., & Evans, C. J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.08.002 · Cited by 122
“The rewarding effects of morphine are mediated via activation of MOP because mice lacking this receptor do not express conditioned place preference and do not self-administer opioid drugs [44].”
The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system
Pugsley, M. K. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00165-1 · Cited by 132
Algera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., & Olofsen, E. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.023 · Cited by 123
Mogil, J. S., & Grisel, J. E. (1998) · Pain · doi:10.1016/s0304-3959(98)00093-1 · Cited by 120
“Kieffer’s group reported the absence of analgesia inm KOs from the d-preferring agonist, Tyr-D-Ser(O-tert-butyl)-Gly-Phe-LeuThr(O-tert-butyl) (BUBU) (Matthes et al., 1996), and decreased DPDPE and D-Ala2-deltorphin II (DELT) analgesia on the tail-withdrawal test, but unalteredd analgesia on the hot-plate test (Matthes…”
BackgroundInfluentialMiess, E., Gondin, A. B., Yousuf, A., Steinborn, R., Mösslein, N., Yang, Y., Göldner, M., Ruland, J. G., Bünemann, M., Krasel, C., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aas9609 · Cited by 119
Sakurada, S., Zadina, J. E., Kastin, A. J., Katsuyama, S., Fujimura, T., Murayama, K., Yuki, M., Ueda, H., & Sakurada, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00181-8 · Cited by 119
Divergent brainstem opioidergic pathways that coordinate breathing with pain and emotions
Liu, S., Ye, M., Pao, G. M., Song, S. M., Jhang, J., Jiang, H., Kim, J., Kang, S. J., Kim, D., & Han, S. (2021) · Neuron · doi:10.1016/j.neuron.2021.11.029 · Cited by 121
Zhang, N., Rogers, T. J., Caterina, M. J., & Oppenheim, J. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.1.594 · Cited by 123
“Disruption of the -opioid receptor in mice results in loss of morphine-induced analgesia, reward, and physical dependence (5).”
BackgroundMeasuring pain in the (knockout) mouse: big challenges in a small mammal
Wilson, S. G., & Mogil, J. S. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00281-9 · Cited by 132
Inflammatory pain is enhanced in delta opioid receptor‐knockout mice
Gavériaux‐Ruff, C., Karchewski, L. A., Hever, X. C., Matifas, A., & Kieffer, B. L. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06223.x · Cited by 127
“Mice lacking mu, delta or kappa opioid receptors were generated by homologous recombination and have been described earlier (Matthes et al., 1996; Simonin et al., 1998; Filliol et al., 2000).”
MethodSelf-citationOpioids and their receptors: Are we there yet?
Pasternak, G. W. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.039 · Cited by 115
“Several groups have generated knockouts of the OPRM1 gene, targeting exon 1(Schuller et al., 1999; Sora et al., 1997), exon 2 or exons 2/3 (Loh et al., 1998; Matthes et al., 1996), or exon 11 (Pan et al., 2009b).”
BackgroundPotassium channels in neuropathic pain: advances, challenges, and emerging ideas
Busserolles, J., Tsantoulas, C., Eschalier, A., & García, J. A. L. (2015) · Pain · doi:10.1097/j.pain.0000000000000368 · Cited by 132
“It is well documented that none of the pharmacological activities of morphine, either its analgesic or adverse effects, is detected in mutant mice lacking mOR.(48) This explains the difficulty to separate beneficial from adverse effects of mOR agonists.”
BackgroundBurford, N. T., Traynor, J. R., & Alt, A. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12599 · Cited by 112
“Morphine-induced analgesia is lost in mice lacking the μ-opioid receptor gene (Matthes et al., 1996).”
BackgroundIkeda, K., Watanabe, M., Ichikawa, T., Kobayashi, T., Yano, R., & Kumanishi, T. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980914)399:1<139::aid-cne11>3.0.co;2-c · Cited by 113
Matsumoto, K., Horie, S., Takayama, H., Ishikawa, H., Aimi, N., Ponglux, D., Murayama, T., & Watanabe, K. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.086 · Cited by 128
Pan, Y.-X., Xu, J., Xu, M., Rossi, G. C., Matulonis, J. E., & Pasternak, G. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811586106 · Cited by 112
Mogil, J. S., Richards, S. P., O’Toole, L. A., Helms, M. L., Mitchell, S. R., & Belknap, J. K. (1997) · Pain · doi:10.1016/s0304-3959(97)03333-2 · Cited by 119
“…issue are recent data showing that transgenic ‘knock-out’ mice lackingm receptors show no alterations in basal nociceptive sensitivity on the HP test (Matthes et al., 1996), whereas mice lacking enkephalin (which binds preferentially to thed receptor) may display altered HP sensitivity (Konig et…”
BackgroundNeurobiology of Kratom and its main alkaloid mitragynine
Suhaimi, F. W., Yusoff, N. H. M., Hassan, R., Mansor, S. M., Navaratnam, V., Müller, C. P., & Hassan, Z. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.015 · Cited by 123
Mas‐Nieto, M., Pommier, B., Tzavara, E. T., Caneparo, A., Nascimento, S. D., Fur, G. L., Roques, B. P., & Noble, F. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703990 · Cited by 111
Self-citationMartin, M., Matifas, A., Maldonado, R., & Kieffer, B. L. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02482.x · Cited by 110
“All animals were F2 from heterozygous breeding pairs and maintained on a hybrid 50% 129/SV: 50% C57Bl/6 genetic background, as in our earlier reports (Matthes et al., 1996; Simonin et al., 1998; Filliol et al., 2000).”
BackgroundMethodInfluentialSelf-citationLeffler, A., Frank, G., Kistner, K., Niedermirtl, F., Koppert, W., Reeh, P. W., & Nau, C. (2012) · Anesthesiology · doi:10.1097/aln.0b013e3182557917 · Cited by 138
Drakenberg, K., Nikoshkov, A., Horváth, M. C., Fagergren, P., Gharibyan, A., Saarelainen, K., Rahman, S., Nylander, I., Bakalkin, G., Rajs, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600871103 · Cited by 109
Thujone Exhibits Low Affinity for Cannabinoid Receptors But Fails to Evoke Cannabimimetic Responses
Meschler, J. P. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00195-6 · Cited by 107
G Protein-Coupled Receptors: Functional and Mechanistic Insights Through Altered Gene Expression
Rohrer, D. K., & Kobilka, B. K. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.35 · Cited by 119
Behavioral Evidence for the Interaction of Oleamide with Multiple Neurotransmitter Systems
Fedorova, I. M., Hashimoto, A., Fecik, R. A., Hedrick, M. P., Hanuš, L. O., Boger, D. L., Rice, K. C., & Basile, A. S. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29334-4 · Cited by 107
The state of GPCR research in 2004
Participants., T. N. R. D. D. G. Q., & Ellis, C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1458 · Cited by 68
Habituation to pain: Further support for a central component
Rennefeld, C., Wiech, K., Schoell, E. D., Lorenz, J., & Bingel, U. (2010) · Pain · doi:10.1016/j.pain.2009.12.014 · Cited by 106
“ratings during the stimulation paradigm as obtained by the VAS [0–100] between days 1 and 8.”
BackgroundMethodResistance to Diet-Induced Obesity in μ-Opioid Receptor–Deficient Mice
Tabarin, A., Diz-Chaves, Y., Carmona, M. D. C., Catargi, B., Zorrilla, E. P., Roberts, A. J., Coscina, D. V., Rousset, S., Redonnet, A., Parker, G. C., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3510 · Cited by 106
Self-citationBook Review: The Pharmacology of Mu Analgesics: From Patients to Genes
Pasternak, G. W. (2001) · The Neuroscientist · doi:10.1177/107385840100700307 · Cited by 106
Lau, E. K., Trester-Zedlitz, M., Trinidad, J. C., Kotowski, S. J., Krutchinsky, A. N., Burlingame, A. L., & von Zastrow, M. (2011) · Science Signaling · doi:10.1126/scisignal.2001748 · Cited by 105
“Despite compelling evidence that morphine mediates its main biological effects through MORs (3), it differs substantially from opioid peptide agonists in various receptor-linked regulatory processes.”
BackgroundReward and aversion processing by input-defined parallel nucleus accumbens circuits in mice
Zhou, K., Xu, H. Z., Lu, S., Jiang, S., Hou, G., Deng, X., He, M., & Zhu, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-33843-3 · Cited by 129
Persistent pain model reveals sex difference in morphine potency
Wang, X., Traub, R. J., & Murphy, A. Z. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00022.2006 · Cited by 115
Opioids and social bonding: naltrexone reduces feelings of social connection
Inagaki, T. K., Ray, L. A., Irwin, M. R., Way, B. M., & Eisenberger, N. I. (2016) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsw006 · Cited by 105
“Downloaded from https://academic.oup.com/scan/article-abstract/11/5/728/1753497 by guest on 30 July 2018 sensitivity to social reward and pain more generally, allelic variation in OPRM1 may also contribute to the effects of opioidblockade on feelings of social connection as measured here and may be an interesting futu…”
Genetic modulation of the pharmacological treatment of pain
Lötsch, J., Geißlinger, G., & Tegeder, I. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.010 · Cited by 114
Glial and neuroinflammatory targets for treating substance use disorders
Bachtell, R. K., Jones, J. D., Heinzerling, K. G., Beardsley, P. M., & Comer, S. D. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.08.003 · Cited by 117
“Attenuating the abuse potential of opioids has proven to be a significant pharmacological challenge as the physiological targets responsible for their abuse liability (mu opioid receptor) also mediate their medicinal value as analgesics (Feltenstein and See, 2008; Matthes et al., 1996).”
BackgroundKremer, M., Yalçın, İ., Goumon, Y., Wurtz, X., Nexon, L., Daniel, D., Megat, S., Ceredig, R. A., Ernst, C., Turecki, G., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1004-18.2018 · Cited by 115
“The generation of mice lacking MOR, DOR, or KOR, created in the laboratory of Brigitte Kieffer (IGBMC, Strasbourg, France), has been described previously (Matthes et al., 1996; Simonin et al., 1998; Filliol et al., 2000).”
Backgroundμ-Opioid receptor-knockout mice: the role of μ-opioid receptor in gastrointestinal transit
Roy, S., Liu, H.-C., & Loh, H. H. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00051-5 · Cited by 103
Activation of TREK-1 by morphine results in analgesia without adverse side effects
Devilliers, M., Busserolles, J., Lolignier, S., Deval, E., Pereira, V., Alloui, A., Christin, M., Mazet, B., Delmas, P., Noel, J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3941 · Cited by 100
“It is well documented that neither the analgesic nor adverse pharmacological activities of morphine can be detected in mutant mice lacking m OR 2 .”
Vekovischeva, O. Y., Zamanillo, D., Echenko, O., Seppälä, T., Uusi-Oukari, M., Honkanen, A., Seeburg, P. H., Sprengel, R., & Korpi, E. R. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04451.2001 · Cited by 102
“Opiates require specific G-protein-coupled receptors for their efficacy, e.g., morphine is acting primarily on m-opioid receptors (Matthes et al., 1996).”
BackgroundMethodGardon, O., Faget, L., Chu Sin Chung, P., Matifas, A., Massotte, D., & Kieffer, B. L. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.053 · Cited by 100
“The MOR has unambiguously been established as the molecular target for opiate drugs, and mediates all the biological activities of morphine including both therapeutic and adverse effects (Matthes et al., 1996, Charbogne et al., 2014).”
BackgroundSelf-citationSmith, J. W., Fetsko, L. A., Xu, R., & Wang, Y. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00257-9 · Cited by 116
Bretaud, S., Li, Q., Lockwood, B. L., Kobayashi, K., Lin, E. T., & Guo, S. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.12.073 · Cited by 111
Bailey, C. P., Llorente, J., Gabra, B. H., Smith, F. L., Dewey, W. L., Kelly, E., & Henderson, G. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06573.x · Cited by 100
“The analgesic, respiratory depressant and rewarding effects of morphine occur through activation of l-opioid receptors (MOPrs; Matthes et al., 1996; Romberg et al., 2003).”
BackgroundCentral opioid receptors mediate morphine-induced itch and chronic itch via disinhibition
Wang, Z., Jiang, C., Yao, H., Ouyang, C., Rahman, S., Gu, Y., Zhao, J., Huh, Y., & Ji, R. (2020) · Brain · doi:10.1093/brain/awaa430 · Cited by 103
Tejedor‐Real, P., Micó, J. A., Smadja, C., Maldonado, R. J., Roques, B. P., & Gibert‐Rahola, J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00423-3 · Cited by 108
Self-citationDautzenberg, F. M., Wichmann, J., Higelin, J., Py-Lang, G., Kratzeisen, C., Malherbe, P., Kilpatrick, G. J., & Jenck, F. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29443-x · Cited by 99
Heteromers of μ‐δ opioid receptors: new pharmacology and novel therapeutic possibilities
Fujita, W., Gomes, I., & Devi, L. A. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12663 · Cited by 98
“Also, studies with mice lacking MOP receptors showed that they exhibited reduced antinociception to DOP receptor-selective agonists compared with wild-type controls (Matthes et al., 1996; British Journal of Pharmacology (2015) 172 375–387 377 1998).”
Mogil, J. S., & Wilson, S. G. (1997) · European Journal of Pain · doi:10.1016/s1090-3801(97)90038-0 · Cited by 99
Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor
Thompson, G. L., Lane, J. R., Coudrat, T., Sexton, P. M., Christopoulos, A., & Canals, M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.098848 · Cited by 98
“Opioids that are currently used as therapeutics, such as morphine, predominantly exert both their analgesic effects and undesirable effects through activation of the m -opioid receptor (MOP) subtype (Matthes et al., 1996; Cox et al., 2015).”
BackgroundChefer, V. I., & Shippenberg, T. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.128 · Cited by 97
“Both analgesia and tolerance of the MOPr agonist, morphine, are abolished in MOPr knockout (KO) mice, indicating that the MOPr is essential for both of these effects (Matthes et al, 1996; Sora et al, 1997).”
Romberg, R. R., Sarton, E. Y., Teppema, L. J., Matthes, H. W. D., Kieffer, B. L., & Dahan, A. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeg279 · Cited by 97
“MOR‐/‐ 46 (17) 42 (18) 49 (21) 36 (16) 46 (13) 49 (6) 47 ( 7 ) 44 (7)”
Self-citationLiu, J. J., Chiu, Y.-T., DiMattio, K. M., Chen, C., Huang, P., Gentile, T. A., Muschamp, J. W., Cowan, A., Mann, M., & Liu‐Chen, L. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0155-0 · Cited by 106
Bailey, C. P., Kelly, E., & Henderson, G. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.004747 · Cited by 109
“The rewarding and analgesic effects of morphine occur through activation of -opioid receptors (MORs) (Matthes et al., 1996).”
BackgroundYao, L., McFarland, K., Fan, P., Jiang, Z., Ueda, T., & Diamond, I. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602661103 · Cited by 101
Ikeda, K., Kobayashi, T., Kumanishi, T., Yano, R., Sora, I., & Niki, H. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00094-9 · Cited by 113
Enkephalin Disinhibits Mu Opioid Receptor-Rich Striatal Patches via Delta Opioid Receptors
Banghart, M. R., Neufeld, S. Q., Wong, N. C., & Sabatini, B. L. (2015) · Neuron · doi:10.1016/j.neuron.2015.11.010 · Cited by 95
“DORs Are the Major Receptor Target of Enkephalin in Patches To determine if activation ofMORmediates the actions of enk, we examined suppression of inhibition in Pdyn-EGFP;Oprm1 / mice (Matthes et al., 1996).”
Zhang, Y., Landthaler, M., Schlussman, S. D., Yuferov, V., Ho, A., Tuschl, T., & Kreek, M. J. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.039 · Cited by 95
“The MOP-r are critical sites for opioid actions of reward (Wise, 1996; Matthes et al., 1996; Sora et al., 2001) as well as analgesia (Matthes et al., 1996; Sora et al., 1997) tolerance to antinociception (Aghajanian, 1978) and physical dependence (Johnson and McCagh, 2000; Matthes et al., 1996).”
BackgroundMorphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide
Roeckel, L.-A., Utard, V., Reiss, D. J., Mouheiche, J., Maurin, H., Robé, A., Audouard, E., Wood, J. N., Goumon, Y., Simonin, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11120-4 · Cited by 108
Self-citationNeuroimmune mechanisms of psychostimulant and opioid use disorders
Hofford, R. S., Russo, S. J., & Kiraly, D. D. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14143 · Cited by 95
“Morphine and other opioids are known to bind opioid receptors to produce reward, dependence, and analgesia (Matthes et al., 1996); however; there is no consensus about which receptor mor-”
BackgroundAn endogenous opioid circuit determines state-dependent reward consumption
Castro, D. C., Oswell, C. S., Zhang, E. T., Pedersen, C. E., Piantadosi, S. C., Rossi, M. A., Hunker, A. C., Guglin, A., Morón, J. A., Zweifel, L. S., et al. (2021) · Nature · doi:10.1038/s41586-021-04013-0 · Cited by 103
How important is protein kinase C in μ-opioid receptor desensitization and morphine tolerance?
Bailey, C. P., Smith, F. L., Kelly, E., Dewey, W. L., & Henderson, G. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.09.006 · Cited by 109
Lu, G., Zhou, Q.-X., Kang, S., Li, Q.-L., Zhao, L.-C., Chen, J.-D., Sun, J.-F., Cao, J., Wang, Y.-J., Chen, J., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0148-10.2010 · Cited by 95
Topical cannabinoid enhances topical morphine antinociception
Yesilyurt, O., Dogrul, A., Gul, H., Seyrek, M., Kusmez, O., Ozkan, Y., & Yildiz, O. (2003) · Pain · doi:10.1016/s0304-3959(03)00245-8 · Cited by 96
“It has been reported that topical antinociceptive effects of morphine were mediated through mu receptors located on the terminals of sensory neurons from the dorsal root ganglia (Kolesnikov et al., 1996; Matthes et al., 1996; Ono et al., 2002).”
BackgroundCadet, P., Mantione, K. J., & Stefano, G. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5118 · Cited by 94
“receptor that is important for agonist selectivity (24, 25).”
BackgroundOpioid receptor random mutagenesis reveals a mechanism for G protein–coupled receptor activation
Décaillot, F. M., Befort, K., Filliol, D., Yue, S. Y., Walker, P., & Kieffer, B. L. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb950 · Cited by 105
Self-citationStegmann, J., Weber, H., Steup, A., Okamoto, A., Upmalis, D. H., & Daniels, S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802448056 · Cited by 94
Abusaad, I., Mackay, D., Zhao, J., Stanford, P., Collier, D. A., & Everall, I. P. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990614)408:4<560::aid-cne9>3.0.co;2-p · Cited by 80
Metadata
- Authors
- Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Surrey (GB)
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- Inserm (FR)
- Venue
- Nature
- Published
- 1996-10
- Volume
- 383
- Issue
- 6603
- Pages
- 819-823
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051746492
- Cited by
- 1,722
- References
- 25
- Citations by year
- 2026: 36 · 2025: 40 · 2024: 45 · 2023: 52 · 2022: 53 · 2021: 56 · 2020: 59 · 2019: 56 · 2018: 53 · 2017: 43 · 2016: 59 · 2015: 53 · 2014: 60 · 2013: 65 · 2012: 58
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- mu-opioid receptor, morphine, analgesia, opioid reward, place preference, opioid withdrawal, physical dependence, knockout mice, delta opioid receptor, kappa opioid receptor, opioid system, pain management
- MeSH terms
- Analgesics, Animals, Behavior, Animal, Cell Line, Enkephalins, Mice, Inbred C57BL, Morphine, Morphine Dependence, Narcotics, Reward, Substance Withdrawal Syndrome, Gene Deletion, Receptors, Opioid, mu, Receptors, Opioid, delta, Receptors, Opioid, kappa, Mice, Knockout, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.